Tenax Therapeutics Inc YBOC-FF:Frankfurt Stock Exchange

RT Quote | Exchange | EUR
Last | 9:04 AM CEST
1.46quote price arrow down-0.01 (-0.68%)
52 week range
0.47 - 2.44

...

Loading . . .
  • Open1.46
  • Day High1.46
  • Day Low1.46
  • Prev Close1.47
  • 52 Week High2.44
  • 52 Week High Date01/19/21
  • 52 Week Low0.47
  • 52 Week Low Date04/22/20

Key Stats

  • Market Cap22.97M
  • Shares Out12.62M
  • 10 Day Average Volume1,791.2
  • Dividend-
  • Dividend Yield-
  • Beta
  • YTD % Change-15.61

KEY STATS

  • Open1.46
  • Day High1.46
  • Day Low1.46
  • Prev Close1.47
  • 52 Week High2.44
  • 52 Week High Date01/19/21
  • 52 Week Low0.47
  • 52 Week Low Date04/22/20
  • Market Cap22.97M
  • Shares Out12.62M
  • 10 Day Average Volume1,791.2
  • Dividend-
  • Dividend Yield-
  • Beta
  • YTD % Change-15.61

RATIOS/PROFITABILITY

  • EPS (TTM)-3.24
  • P/E (TTM)-0.45
  • Fwd P/E (NTM)-
  • EBITDA (MRQ)-
  • ROE (MRQ)-
  • Revenue (MRQ)-
  • Gross Margin (MRQ)-
  • Net Margin (MRQ)-
  • Debt To Equity (MRQ)-

EVENTS

  • Earnings Date-
  • Ex Div Date-
  • Div Amount-
  • Split Date-
  • Split Factor-

Latest From Tenax Therapeutics Inc

There is no recent news for this security.

Profile

MORE
Tenax Therapeutics, Inc. is a specialty pharmaceutical company. The Company is focused on identifying, developing and commercializing products for the critical care market. The Company's main product is levosimendan. Levosimendan is a calcium sensitizer developed for intravenous use in hospitalized patients with acutely decompensated heart failure. Levosimendan represents therapeutic modalities for the treatment of Low Cardiac Output Syndrome (LCOS), septic shock and other...
Ronald Blanck
Non-Executive Chairman
Anthony DiTonno
Chief Executive Officer
Michael Jebsen CPA
President
Doug Randall
Executive Vice President
Douglas Hay Ph.D.
Executive Vice President
Address
One Copley Parkway, Suite 490
Morrisville, NC
27560
United States